8-K: Medicus Pharma Secures $15 Million Standby Equity Purchase Agreement and Plans TSXV Delisting

Medicus Pharma Ltd. enters into a Standby Equity Purchase Agreement with YA II PN, LTD for up to $15 million and announces its intention to voluntarily delist from the TSX Venture Exchange.

Summary

• Medicus Pharma Ltd. has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD, allowing the company to sell up to $15 million of its common shares over the next 36 months.
• The shares will be sold at 97% of the market price during a specified three-day pricing period, and Medicus reserves the right to set a minimum acceptable price.
• Medicus intends to use the proceeds to fund its Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma and potentially expand its trials to cover other non-melanoma skin diseases, with any remaining proceeds used for general corporate purposes and working capital.
• As consideration for Yorkville's commitment, Medicus paid a $25,000 structuring fee and issued 105,840 common shares.
• The company's board of directors has approved the voluntary delisting of its common shares from the TSX Venture Exchange (TSXV).
• Medicus will remain a reporting issuer in Canada and will continue to provide disclosure on SEDAR+ as required by applicable Canadian securities laws.
• The company has submitted an application to the TSXV to complete such delisting, which is subject to the approval of the TSXV and the satisfaction of all necessary conditions.
• Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market under the symbol 'MDCX'.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The SEPA provides funding, but also introduces potential dilution. The TSXV delisting is likely a cost-saving measure, but could impact some shareholders.

Positives

• The $15 million SEPA provides Medicus Pharma with access to capital to fund its clinical trials and operations.
• The delisting from the TSXV is expected to streamline trading and reduce administrative costs.
• The Phase 2 clinical trial for basal cell carcinoma treatment has the potential to create value for the company.
• Medicus will remain a reporting issuer in Canada and will continue to provide disclosure on SEDAR+ as required by applicable Canadian securities laws.

Negatives

• The SEPA involves selling shares at 97% of the market price, which could dilute existing shareholders.
• The total number of Shares issuable under the terms of the SEPA is limited to a number equivalent to 19.99% of the outstanding Shares as of the date of the SEPA unless certain pricing conditions are met, which could have the effect of limiting the total proceeds made available to the Company under the SEPA.
• The issuance of Shares under the SEPA is subject to further limitations, including that the Shares beneficially owned by the Investor and its affiliates at any one time will not exceed 4.99% of the then-outstanding Shares.
• The delisting from the TSXV could reduce trading options for some Canadian shareholders, although the majority of trading volume occurs on the NASDAQ.

Risks

• The company's ability to draw down funds under the SEPA is subject to certain conditions, including the effectiveness of a registration statement with the SEC.
• Clinical trials are inherently risky, and there is no guarantee that the Phase 2 trial will be successful.
• The company's stock price could be negatively impacted by the issuance of new shares under the SEPA.
• The company's stock price could be negatively impacted by the delisting from the TSXV.

Future Outlook

Medicus Pharma intends to use the proceeds from the SEPA to fund its Phase 2 clinical trial for basal cell carcinoma and potentially expand its trials to cover other non-melanoma skin diseases. The company expects its shares to continue trading on the NASDAQ Capital Market.

Management Comments

• Given the low trading volume on the TSXV, the Company has determined, after due consideration, that maintaining the TSXV listing does not form part of the Company's go-forward capital markets strategy.

Industry Context

Standby Equity Purchase Agreements are a relatively common financing tool for small-cap biotech companies, providing access to capital while allowing flexibility in timing and amount. Delisting from smaller exchanges like the TSXV to focus on larger exchanges like NASDAQ is also a common strategy to consolidate trading and potentially attract a broader investor base.

Comparison to Industry Standards

• Similar biotech companies, such as [Hypothetical Biotech Company A] and [Hypothetical Biotech Company B], have utilized similar SEPA agreements to fund clinical trials.
• The terms of the SEPA, including the 97% of market price and the limitations on share issuance, are generally consistent with industry standards for these types of agreements.
• Delisting from smaller exchanges to focus on NASDAQ is a strategy employed by companies like [Hypothetical Company C] to improve trading liquidity and visibility.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares under the SEPA.
• Canadian shareholders who primarily trade on the TSXV may need to adjust their trading strategies following the delisting.
• The company's employees and management will be focused on executing the clinical trial and managing the financing agreement.
• The company's customers and partners may benefit from the company's ability to fund its clinical trials and commercialization efforts.

Next Steps

• Medicus Pharma will file a registration statement with the SEC to register the resale of shares issued under the SEPA.
• The company will seek approval from the TSXV for the voluntary delisting.
• Medicus Pharma will continue patient recruitment for its Phase 2 clinical trial (SKNJCT-003).

Key Dates

Keywords

Standby Equity Purchase Agreement, SEPA, Medicus Pharma, YA II PN, LTD, TSXV Delisting, Clinical Trial, Basal Cell Carcinoma, NASDAQ, Equity Financing, MDCX